HER2 TKIs, such as lapatinib, are used in breast cancer with amplified HER2 [3] while Vascular Endothelial Growth Factor Receptor (VEGFR) TKIs and multitarget TKIs are commonly employed in renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, gastrointestinal stromal tumors (GIST), and in previously treated colorectal cancer [4-7]. This evidence concerns the gene ERBB2 and renal cell carcinoma.